|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-3-22
|
|
pubmed:abstractText |
The overall 5-year survival rate of approximately 60% for head and neck cancer patients has remained essentially unchanged over the past 30 years. MicroRNA-137 (miR-137) plays an essential role in cell-cycle control at the G1/S-phase checkpoint. However, the aberrant miR-137 promoter methylation observed in squamous cell carcinoma of the head and neck (SCCHN) suggests a tumor-specific molecular defect that may contribute to disease progression.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
117
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1454-62
|
|
pubmed:meshHeading |
pubmed-meshheading:21425146-Carcinoma, Squamous Cell,
pubmed-meshheading:21425146-DNA Methylation,
pubmed-meshheading:21425146-Disease-Free Survival,
pubmed-meshheading:21425146-Female,
pubmed-meshheading:21425146-Head and Neck Neoplasms,
pubmed-meshheading:21425146-Humans,
pubmed-meshheading:21425146-Male,
pubmed-meshheading:21425146-MicroRNAs,
pubmed-meshheading:21425146-Middle Aged,
pubmed-meshheading:21425146-Prognosis,
pubmed-meshheading:21425146-Promoter Regions, Genetic
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck.
|
|
pubmed:affiliation |
University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, Pennsylvania 15213-1863, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
